CONMED (NYSE: CNMD) VP granted 17,471 RSUs under 2025 incentive plan

Rhea-AI Filing Summary

Schabacker Matthew reported acquisition or exercise transactions in this Form 4 filing.

CONMED Corporation reported an amended Form 4 showing that executive Matthew Schabacker, VP GM Advanced Surgical, received a corrected grant of 17,471 restricted stock units (RSUs) under the company’s 2025 Long-Term Incentive Plan.

Each RSU represents a contingent right to one share of CONMED common stock. The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% in the second year, and 34% in the third year. The amendment clarifies that this total includes a special award of 7,644 RSUs in addition to the originally reported 9,827 RSUs.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schabacker Matthew

(Last) (First) (Middle)

C/O CONMED CORPORATION

11311 CONCEPT BOULEVARD

(Street)

LARGO FL 33773

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP GM Advanced Surgical

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
RSUs (Restricted Stock Units)	$0	03/02/2026		A		17,471		(1)	03/02/2036	Common Stock	17,471(2)	$0	17,471	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.

2. This Form 4/A is filed solely to correct the amount of RSUs granted. A special award of 7,644 shares was awarded in addition to the originally reported 9,827 shares for a total of 17,471 RSUs granted.

	/s/ Thomas Fistek for Matthew Schabacker by Power of Attorney	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CONMED (CNMD) report in this Form 4/A?

CONMED reported a corrected grant of 17,471 restricted stock units to executive Matthew Schabacker. The filing clarifies his equity-based compensation under the 2025 Long-Term Incentive Plan and replaces a previously understated RSU amount.

How many RSUs were granted to CONMED (CNMD) executive Matthew Schabacker?

Matthew Schabacker was granted a total of 17,471 restricted stock units. This consists of the originally reported 9,827 RSUs plus a special award of 7,644 RSUs, as corrected in the amended Form 4/A filing.

How do the CONMED (CNMD) RSUs granted to Schabacker vest over time?

The 17,471 RSUs generally vest over a three-year period. According to the disclosure, 33% vest one year after the grant date, another 33% in the second year, and the remaining 34% in the third year, subject to plan terms.

What does each CONMED (CNMD) RSU represent in this Form 4/A?

Each restricted stock unit represents a contingent right to receive one share of CONMED common stock. The RSUs are issued under the company’s 2025 Long-Term Incentive Plan and remain subject to its terms and the specified vesting schedule.

Why did CONMED (CNMD) file this Form 4/A amendment?

The amendment was filed solely to correct the number of RSUs granted to Matthew Schabacker. It clarifies that a special award of 7,644 RSUs was added to the originally reported 9,827 RSUs, bringing the total grant to 17,471 RSUs.

What position does Matthew Schabacker hold at CONMED (CNMD)?

Matthew Schabacker serves as Vice President and General Manager, Advanced Surgical. The amended Form 4 shows an equity award of 17,471 RSUs to him under CONMED’s 2025 Long-Term Incentive Plan, reflecting his compensation structure.